DeCIDE and PARADIGM: nails in the coffin of induction chemotherapy in head and neck squamous cell carcinoma?
- 606 Downloads
Induction chemotherapy was first used in squamous cell carcinoma of the head and neck (SCCHN) in the 1970s. High overall response rates were observed in previously untreated tumours  and a correlation between response to induction chemotherapy and favourable outcome following radiotherapy was noted . Numerous subsequent randomised studies and meta-analyses nonetheless failed to demonstrate a significant survival advantage with the use of induction chemotherapy compared with locoregional treatment alone . A marginally significant 5 % absolute improvement in 5 year survival was seen when analysis was restricted to studies using a platin and 5-fluorouracil (PF) as the induction regimen. This was however overshadowed by the larger survival benefit observed with concurrent chemoradiation (CRT). As a result, CRT became widely accepted as the standard of care in the non-surgical management of patients with locoregionally advanced SCCHN.
Recent years have witnessed a renewed interest...
KeywordsDocetaxel Induction Chemotherapy DeCIDE Trial Slow Accrual Advanced Nodal Disease
Conflict of interest
- 1.Argiris A, Jayaram P, Pichardo D (2005) Revisiting induction chemotherapy for head and neck cancer. Oncology (Williston Park) 19:759–770Google Scholar
- 6.Cohen EEW, Karrison T, Kocherginsky M et al (2012) DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30:abstract 5500Google Scholar
- 7.Haddad RI, Rabinowits G, Tishler RB et al (2012) The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC). J Clin Oncol 30:abstract 5501Google Scholar